ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
| Autor: | Dinesh Chandra Doval, Bharti Dabas, Manoj Kumar Panigrahi, Moushumi Suryavanshi, Mumtaz Saifi, Dushyant Kumar, Ullas Batra, Anurag Mehta, Haristuti Verma |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine EGFR Cell 03 medical and health sciences Anaplastic lymphoma kinase 0302 clinical medicine medicine ROS1 Carcinoma lcsh:RC705-779 crizotinib Lung medicine.diagnostic_test Crizotinib business.industry lcsh:Diseases of the respiratory system medicine.disease 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Cancer research Adenocarcinoma Original Article business Fluorescence in situ hybridization medicine.drug |
| Zdroj: | Lung India, Vol 34, Iss 5, Pp 411-414 (2017) Lung India : Official Organ of Indian Chest Society |
| ISSN: | 0970-2113 |
| Popis: | Background: The frequency of ROS1 rearrangement in non-small cell lung cancers has been reported from 1.6% to 2.3%. Materials and Methods: We examined 105 lung adenocarcinoma patients for ROS1 rearrangement which were negative for EGFR and anaplastic lymphoma kinase. Clinical characteristics of ROS1 rearranged patients and their responses to crizotinib therapy were studied. Results: Of the 105 patients, three cases were positive for ROS1 rearrangement by fluorescence in situ hybridization analysis. All of them showed heterogeneous pattern. All the 3 ROS1-positive patients were females in their forties and started on crizotinib. All of them responded to treatment. One of them developed resistance after 3 months. Another one showed marked systemic response but central nervous system lesions progressed. The third case is doing well till date with inactive lesions on positron emission tomography scan. Conclusions: The frequency of ROS1 rearrangement is low in non-small cell lung carcinoma, but their diagnosis offers patients an opportunity to receive highly effective targeted therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|